Condition
EGFR Exon 21 Mutation
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownObservational Multicenter Study in Patients Receiving Chemotherapy and Amivantamab for Metastatic Non-small Cell Lung CancerNCT07563205 · 2025-11-19
RECRUITINGBefotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC PatientsNCT07709585 · 2026-07-05
NOT_YET_RECRUITINGA Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.NCT06142617 · 2023-12-01
NOT_YET_RECRUITINGStudy to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)NCT05998993 · 2023-11-01
NOT_YET_RECRUITINGCommon interventions
Leading sponsors
Trial status mix
NOT_YET_RECRUITING3
RECRUITING1
Phase mix
PHASE22
NA1
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.